Physician
Sarij, Hasib
Sarij, Hasib was paid $405K by Medicaid between Jan 2018 and Feb 2024, across 20 billing codes. Its largest line is J3490, Unclassified drugs — 28% of everything it billed.
33Billing provider infoSARIJ, HASIB
FARMINGDALE, NY 11735
FARMINGDALE, NY 11735
33aNPI1992888184assigned 10/23/2006
33bProvider typeInterventional Pain Medicine Physician
28Total paid$405K
24GClaims28,357
24DCodes billed20
24AFirst – last monthJan 2018 – Feb 2024
Compared with peers
Next to other Interventional Pain Medicine Physician providers in New York
Rank by total paid#12 of 58
Median peer was paid$24K
This provider vs. median17×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,326 | $79K | |
| 2019 | 4,938 | $115K | |
| 2020 | 6,376 | $78K | |
| 2021 | 6,022 | $77K | |
| 2022 | 4,771 | $39K | |
| 2023 | 2,642 | $10K | |
| 2024incomplete | 282 | $6K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J3490 | Unclassified drugs | 28% | 767 | 661 | $111K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 24% | 5,041 | 4,375 | $96K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 3,761 | 3,168 | $61K |
| 76942 | 12% | 2,859 | 2,546 | $48K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 9.5% | 1,229 | 1,125 | $39K |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | 5.0% | 556 | 473 | $20K |
| 20553 | 3.5% | 1,692 | 1,566 | $14K | |
| 80305 | 1.9% | 2,970 | 2,631 | $8K | |
| 20552 | 1.3% | 452 | 421 | $5K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 14 | 14 | $1K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 471 | 417 | $501.08 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,622 | 1,408 | $474.95 |
8 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 307 | $458.78 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 46 | $436.25 |
| 99072 | <1% | 1,821 | $369.32 | |
| 77003 | <1% | 13 | $130.28 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 725 | $41.25 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,295 | $6.75 |
| G8484 | Influenza immunization was not administered, reason not given | 0% | 925 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 1,791 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.